Erivedge vismodegib: Phase II data

Interim data from 17 evaluable patients in a single-arm, open-label, French Phase II trial showed that once-daily 150 mg oral vismodegib led to 4 cases of stable disease at 6 months, meeting the criteria for continued enrollment. Vismodegib was well tolerated. The trial, which has enrolled 40 patients, is being conducted by the Institut Bergonie. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...